REGN Share Price

Open 513.00 Change Price %
High 521.51 1 Day -1.42 -0.27
Low 506.70 1 Week 20.58 4.15
Close 515.91 1 Month 60.74 13.34
Volume 1172460 1 Year 184.86 55.84
52 Week High 543.55
52 Week Low 325.35
REGN Important Levels
Resistance 2 529.64
Resistance 1 523.98
Pivot 514.71
Support 1 507.84
Support 2 502.18
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 37.50%
FNFG 10.18 -0.20%
AVEO 1.95 56.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AVEO 1.95 56.00%
LOCM 0.09 50.00%
DCTH 0.22 37.50%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
OPXAW 0.15 25.00%
PTSX 0.15 25.00%
FRED 12.61 23.02%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

REGN Technical Analysis 5
As on 26th Jun 2017 REGN Share Price closed @ 515.91 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 397.22 & Strong Buy for SHORT-TERM with Stoploss of 436.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
REGN Target for June
1st Target up-side 500.58
2nd Target up-side 529.68
3rd Target up-side 558.78
1st Target down-side 417.54
2nd Target down-side 388.44
3rd Target down-side 359.34
REGN Other Details
Segment EQ
Market Capital 13942355968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.regeneron.com
REGN Address
REGN
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-347-7000
REGN Latest News
Interactive Technical Analysis Chart Regeneron Pharmaceuticals, Inc. ( REGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regeneron Pharmaceuticals, Inc.
REGN Business Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.